Company intelligence / Profile preview

Nanoscope Therapeutics

Dallas, Texas, United Statesnanostherapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Nanoscope Therapeutics has reported positive top-line results from its RESTORE Phase 2b trial of MCO‑010 in retinitis pigmentosa, achieving primary and key secondary endpoints with statistical significance and no serious adverse events. The therapy demonstrated clinically meaningful vision improvement in legally blind individuals. A BLA submission to the FDA is planned for the second half of 2024. The company’s STARLIGHT trial of MCO‑010 in Stargardt disease has also been completed. Both indications have received FDA fast-track and orphan drug designations.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (optogenetic)Ambient light-sensitive molecules (Multi-characteristic opsins)
Industry: Biotech

Drug pipeline

6 assets

sonpiretigene isteparvovec

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nanoscope Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanoscope Therapeutics.

Explore the full profile